Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0317-2027

Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103 Recall

Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103

FDA recall Class II

Ongoing

FDA lists this Class II recall for Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0317-2027
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Sep 14, 2026
FDA report date
Nov 11, 2026
Quantity in commerce
28710
Distribution
See key details
FDA cause
Process control

What is being recalled?

Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103

Affected model & UDI checker

Search the exact identifiers published for Z-0317-2027.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
J103Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103Check source noticeNot specified
FDA code information

UDI-DI: 10711234103012, Lot(Expiration): B6JCA005(02/28/2027), C6JCA008(03/31/2027), D6JCA011(04/30/2027), K5JCA041(10/31/2026), C6JCA007(03/31/2027)

View the original FDA recall notice

Why was this product recalled?

Microcoagulation test used to evaluate low dose heparin anticoagulation has a mispositioned or absent clot activating reagent, which may result in out-of-range high error code, or erroneously high results, which may lead retest, or overestimation of patient's anticoagulation, leading to inadequate anticoagulant therapy, which could result in thrombosis.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Accriva Diagnostics, Inc. take?

On 9/14/2026, recall notices were mailed to customers who were informed of the following: 1) Please forward this communication to those within your organization who need to be aware of this matter and verify they understand the procedure and can complete the enclosed forms. 2) Forward the enclosed customer notification to all other organizations where affected devices may have been transferred to. 3) Please check your inventory and do not use affected lots. 4) Scrap/destroy all impacted cuvettes and/or boxes. 5) Complete and return the Acknowledgement and Receipt Form via email to ilsd_ra.na@werfen.com Questions about receiving credit, should be directed to Customer Service at 1-800-955-9525 or e-mail customerservice.na@werfen.com. Technical questions should be directed to Technical Services at 1-800-678-0710 Option 3 or email techsupport.na@werfen.com.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology